GX-188E: Interim Phase II data

Interim data from 33 CIN3 patients with HPV genotype 16/18 infection in an open-label, South Korean Phase II trial showed that 1 mg intramuscular GX-188E at weeks 0, 4 and 12 led to a “therapeutic eff...